中国肺癌杂志2017，Vol.20Issue(4)：278-286,9.DOI:10.3779/j.issn.1009-3419.2017.04.09
晚期非小细胞肺癌靶向治疗进展与展望:聚焦小分子酪氨酸激酶抑制剂
Recent Advances and Prospect of Advanced Non-small Cell Lung Cancer Targeted Therapy: Focus on Small Molecular Tyrosine Kinase Inhibitors
张国伟 1王慧娟1
作者信息
- 1. 450003郑州,郑州大学附属肿瘤医院(河南省肿瘤医院)内科
- 折叠
摘要
Abstract
At present the treatment of advanced non-small cell lung cancer enters a targeted era and develops rapidly.New drugs appear constantly.Small molecular tyrosine kinase inhibitors have occupied the biggest piece of the territory,which commonly have a clear biomarker as predictor,and show remarkable effect in specific molecular classification of patients.Tne epidermal growth factor tyrosine kinase inhibitors such as gefitinib,erlotinib,icotinib and anaplastic lymphoma kinase tyrosine kinase inhibitors crizotinib have brought a milestone advance.In recent years new generations of tyrosine kinase inhibitors have achieved a great success in patients with acquired resistance to the above two kinds of drugs.At the same time new therapeutic targets are constantly emerging.So in this paper,we reviewed and summarized the important drugs and clinical trails on this topic,and made a prospect of the future development.关键词
肺肿瘤/靶向治疗/生物标记/EGFR/ALKKey words
Lung neoplasms/Molecular targeted therapy/Biomarker/EGFR/ALK引用本文复制引用
张国伟,王慧娟..晚期非小细胞肺癌靶向治疗进展与展望:聚焦小分子酪氨酸激酶抑制剂[J].中国肺癌杂志,2017,20(4):278-286,9.
